However, the apparent requirement for months-long intratumoral administration of the anti-TGFB2 S-ODN OT-101 for achieving objective responses in high-grade adult glioma patients [37], combined with the practical challenges of prolonged use of implanted CED catheters or repeated replacement surgeries for CED catheters at this difficult anatomic location, indicates that discovery of innovative delivery methods and/or formulation strategies will likely be required for TGFB2-targeting RNAi therapeutics to be effective in DIPG patients. The gene discussed is TGFB2; the disease is glioma.